Kobieta w średnim wieku ćwicząca na maszynie na siłowni

Gustavo Fring / Pexels

Perimenopause and Weight Gain: What Does the 21-Year SWAN Study Show?

"I gained weight around menopause and nothing works" is one of the most repeated complaints from women in their forties and beyond. The largest long-term cohort study on the topic — the Study of Women's Health Across the Nation (SWAN) — shows this isn't just perception: the rate of fat gain genuinely doubles at a specific, predictable point in the menopause transition. We check exactly what changes, why hormone therapy isn't a simple fix, and what intervention studies actually show.

PZdr Piotr ZielińskiSeptember 4, 202614 min read

Table of contents

TL;DR — key takeaways

→"Nothing changed in my diet, but I'm still gaining weight" — is that possible?
→What the 21-year SWAN study showed
→Not just more fat — where it's stored also changes
→Why this happens — the hormonal mechanism
→Does hormone therapy solve this problem?
→What other hormone therapy studies show
→What actually helps during this period
→Limitations of this data
→Our editorial recommendation

"Nothing changed in my diet, but I'm still gaining weight" — is that possible?

Complaints about weight gain in the forties and fifties, despite no change in diet or physical activity, are among the most frequently repeated by women in an endocrinologist's office. For decades, this was treated more as a subjective feeling tied to aging in general than a concrete, measurable process linked to the menopause transition. The largest and longest-running cohort study on this topic — the Study of Women's Health Across the Nation (SWAN) — has provided hard data that largely confirms this widespread complaint, while pinpointing exactly when the change occurs and what it involves.

This article isn't about menopause in general — we cover menopause itself and its other symptoms more broadly in our knowledge base. Here we focus exclusively on one specific phenomenon: the change in body composition and rate of fat gain during the menopause transition (perimenopause), based on one of the most reliable sources of data we have on this topic.

Perimenopause is the transitional period, not menopause itself

Perimenopause refers to the years leading up to the final menstrual period (menopause), during which sex hormone levels begin to fluctuate and gradually decline. It's precisely within this window — not only after menopause itself — that the SWAN study found the largest changes in the rate of fat gain.

What the 21-year SWAN study showed

Changes in body composition and weight during the menopause transition

Strong evidence

Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K et al. · JCI Insight · 2019

An analysis of data from the long-term, observational SWAN cohort study included 3,302 women aged 42-52 at enrollment, followed for 21 years — from roughly 9 years before the final menstrual period to 10 years after, with body composition measured by DXA. About 2 years before the final menstrual period, the rate of fat gain doubled — from roughly 1% per year to about 1.7% per year — while lean (muscle) mass simultaneously began to decline. This accelerated fat gain and lean mass loss persisted throughout the menopause transition, until about 2 years after the final menstrual period, after which the rate of change slowed again.

The key takeaway from this study is precise: it's not that women simply "gain weight with age" at a constant rate over decades. The change has a specific time window — starting about 2 years before the final period and lasting roughly until 2 years after — making it a phenomenon linked to specific hormonal changes of the menopause transition, not merely chronological aging of the body.

Not just more fat — where it's stored also changes

Increased visceral fat and decreased energy expenditure during the menopausal transition

Moderate evidence

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR · International Journal of Obesity · 2008

A 4-year longitudinal study of 156 women (with a 34-person subset undergoing calorimetry) tracked changes in body composition, fat distribution, and energy balance during the perimenopausal period. A significant increase in both total body fat AND visceral fat (surrounding internal organs) occurred only in the group of women who transitioned through menopause during the study — women who remained premenopausal throughout the observation period showed no such increase in visceral fat. Additionally, sleeping energy expenditure decreased 1.5-fold more in postmenopausal women than in those remaining premenopausal (-7.9% vs. -5.3%), and fat oxidation decreased by 32% (p<0.05).

Why fat distribution matters clinically

Moderate evidence

Visceral fat, unlike subcutaneous fat, is more strongly linked to cardiovascular risk, insulin resistance, and metabolic syndrome. The fact that the increase in visceral fat in this study occurred specifically in women transitioning through menopause, not in those remaining premenopausal during the same period, suggests a hormonal mechanism rather than simply an effect of aging or lifestyle shared by both groups.

Why this happens — the hormonal mechanism

Estrogen influences fat distribution and energy metabolism in several ways — among others, by promoting fat storage in the hips and thighs ("pear" pattern) at the expense of visceral storage around the abdomen ("apple" pattern). As estrogen levels decline during the menopause transition, this protective tendency weakens, favoring a shift toward visceral fat storage, independent of total calories consumed. Additionally, the muscle mass loss observed during the same period lowers resting metabolic rate, since muscle tissue burns more energy at rest than fat tissue — meaning that with the exact same diet and physical activity, the body starts burning slightly less energy than before.

This explains why "nothing changed" but weight still climbs

If diet and physical activity stay exactly the same, but resting energy expenditure drops due to muscle mass loss, the net effect is a positive energy balance leading to fat gain — without any change in behavior. This isn't a matter of "lacking willpower," but a measurable physiological shift.

Does hormone therapy solve this problem?

Since declining estrogen plays a mechanistic role, a logical question is whether menopausal hormone therapy (HRT) prevents this weight gain and shift in fat distribution. The answer from randomized trials is more ambiguous than one might expect.

The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial

Moderate evidence

Sites CK, L'Hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA · Journal of Clinical Endocrinology & Metabolism · 2005

76 postmenopausal women were randomized to conjugated estrogens plus medroxyprogesterone acetate or placebo for 2 years, with assessments every 6 months (51 women completed the trial: 26 on HRT, 25 on placebo). Visceral fat, subcutaneous abdominal fat, total body fat, percent body fat, lean mass, and body weight did not differ significantly between groups at any point during the trial. Hormone therapy thus had no effect on body composition or fat distribution in this particular trial. Additionally, insulin sensitivity decreased by 17% in the HRT group at 6 months and stayed at that level for 2 years, though the effect proved reversible — one year after the trial ended, insulin sensitivity in the former HRT group increased by 25%.

Myth

Menopausal hormone therapy prevents weight gain and changes in body shape during menopause.

Fact

In the randomized, placebo-controlled trial by Sites et al. (2005), hormone therapy had no significant effect on body composition, body weight, or fat distribution compared to placebo over 2 years of follow-up — and additionally temporarily worsened insulin sensitivity. Other studies and reviews show a somewhat more favorable picture for central fat, but the general consensus is that HRT is neither an approved nor a reliable method of weight control during menopause.

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Find supplements for me

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

What other hormone therapy studies show

It's worth noting that not all studies on HRT and body composition produce an identical null result to Sites et al. — some larger reviews and cohort analyses point to a modest, favorable reduction in central fat (waist circumference, waist-to-hip ratio) with hormone therapy compared to non-users. Discrepancies between studies partly stem from different hormone formulations, doses, routes of administration, and timing of therapy initiation relative to menopause. Nevertheless, no reliable source recommends HRT as a primary treatment for obesity or weight control — its main indication remains relief of vasomotor and other menopausal symptoms, with any effect on body composition being a secondary outcome rather than the therapy's main goal.

A decision about hormone therapy shouldn't rest on an expectation of weight control

Menopausal hormone therapy carries its own profile of benefits and risks (including thromboembolic risk and certain hormone-dependent cancers), independent of any effect on weight. The decision to start it should be made with a doctor, taking into account individual risk profile and severity of menopausal symptoms — not an expectation of weight control, which, as some studies show, may not materialize.

What actually helps during this period

Interventions with the best-documented effect during the perimenopausal period

Strength training, aimed at preserving and building muscle mass — counteracts the drop in resting metabolic rate that accompanies muscle loss during this period
Adequate dietary protein intake, supporting muscle mass maintenance during any indicated calorie deficit
Regular moderate-intensity physical activity — intervention studies show that combining exercise with dietary intervention can limit the typical increase in adiposity during this period
Monitoring not just body weight but also waist circumference — given the documented shift toward visceral fat, weight alone may not reflect the full picture of metabolic changes
Realistic expectations of hormone therapy — its main goal is relieving menopausal symptoms, not weight control

Limitations of this data

What these studies don't prove

The SWAN study is observational, meaning that despite its large sample and long follow-up, it doesn't prove direct causation in an experimental sense — though consistency with independent mechanistic research (like Lovejoy et al.) strengthens confidence in the conclusion about a hormonal basis for the phenomenon. The Sites et al. HRT trial had a relatively small sample (51 people completed it) and evaluated one specific hormone formulation at one dose — the results may not fully generalize to other hormone therapy regimens. None of the cited studies directly assesses the effect of specific dietary interventions or supplements on this process in a way that allows precise dosing recommendations.

Question	Short answer
Is weight gain around menopause real, not just perceived?	Yes — the SWAN study (n=3,302, 21-year follow-up) shows the rate of fat gain doubles about 2 years before the final period
Does only the amount of fat change, or also where it's stored?	Distribution changes too — the increase in visceral fat occurred specifically in women transitioning through menopause
Does hormone therapy prevent this weight gain?	No consistent evidence for that — the Sites et al. RCT found no significant effect of HRT on body composition
Why does weight rise despite the same diet?	Muscle mass loss lowers resting energy expenditure, which, with the same diet, leads to a positive calorie balance
What has the best-documented effect during this period?	Strength training and adequate protein intake, aimed at preserving muscle mass

Perimenopause and weight gain at a glance

Our editorial recommendation

The SWAN study is one of those rare cases in medicine where a long-standing, widespread patient complaint finds precise confirmation in hard longitudinal data — the rate of fat gain genuinely doubles within a specific time window linked to the menopause transition, rather than being purely an effect of aging or "poorer discipline." At the same time, it's important to manage expectations about hormone therapy — it's not a weight-control method, and the interventions with the best-documented effect (strength training, adequate protein intake) remain the same as at any other stage of life, just becoming more important right now.

Patients have been telling us for years this isn't a matter of willpower — the SWAN study finally gave us data confirming that with numbers, not just sympathy. That doesn't excuse anyone from physical activity, but it changes how we talk about this period.

Dr. Piotr Zieliński, VitMode editorial team

Frequently asked questions

According to the SWAN study, the rate of fat gain starts to double about 2 years before the final menstrual period and stays elevated until about 2 years after, after which it gradually returns to the earlier rate.

No — the studies show average trends across large groups of women, but individual differences due to genetics, physical activity level, and diet are significant. Not every woman will experience an identical pattern of change.

There's no consistent evidence for that. A randomized, placebo-controlled trial found no significant effect of hormone therapy on body composition or body weight compared to placebo. The main indication for HRT remains relief of menopausal symptoms, not weight control.

Declining estrogen weakens its protective effect on fat distribution, favoring a shift in fat storage from the hips and thighs toward the abdomen (visceral area) — regardless of total calories consumed.

Not necessarily. Given the documented shift toward visceral fat, it's worth also monitoring waist circumference, since body weight alone may not fully reflect changes in fat distribution and the associated metabolic risk.

Strength training combined with adequate dietary protein has the best-documented effect on preserving muscle mass, which indirectly helps keep resting metabolic rate at a higher level.

The SWAN study is observational, so it doesn't prove direct causation in an experimental sense. However, its consistency with an independent mechanistic study (Lovejoy et al.), which showed increased visceral fat specifically in women transitioning through menopause, strengthens confidence in the conclusion about a hormonal basis for this phenomenon.

Sources

PZ

dr Piotr Zieliński

Specialist physician in endocrinology, scientific consultant

Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.

Related articles

Mierzenie obwodu talii taśmą centymetrową

TRT and Weight Loss — Does Testosterone Therapy Actually Help You Lose Weight?

Testosterone replacement therapy genuinely changes body composition in men with hypogonadism — less fat, more muscle — but it isn't a weight-loss drug, and the number on the scale after TRT often barely changes.

August 15, 2026

Lekarka w białym fartuchu rozmawiająca z pacjentką podczas konsultacji w gabinecie

Hormone Replacement Therapy in Menopause: Who Should Consider It, When, and What's the Real Risk?

The 2002 WHI study triggered a global panic around hormone replacement therapy, and prescriptions dropped by half almost overnight. Two decades of further analysis have painted a much more nuanced picture — one that depends above all on age and timing of initiation. We explain what the data actually show, who has a favorable risk-benefit balance today, and who should exercise particular caution.

August 22, 2026

Kobieta w średnim wieku z wachlarzem w słońcu

Black Cohosh and Menopause Symptoms — What Does the Network Meta-Analysis Show?

Black cohosh (Actaea racemosa, also known as Cimicifuga racemosa) is one of the most popular herbal supplements for hot flashes and night sweats during menopause — marketed as a hormone-free alternative to hormone replacement therapy. A large network meta-analysis prepared for the UK's NICE menopause guideline did place it among the options more effective than placebo, but the picture is more nuanced than pharmacy packaging suggests.

August 27, 2026

Starsza kobieta ćwicząca z hantlami w pomieszczeniu

Strength Training for Women Over 40 — Where to Start

The decline in muscle mass, bone density, and metabolic rate after forty isn't a life sentence — it's largely reversible with strength training, even if you've never picked up a barbell before. This guide shows how to start safely, how much load you actually need, and what to avoid in the first few weeks.

September 3, 2026

Related knowledge base entries

Menopause

The permanent cessation of menstruation caused by the ovaries ceasing function — a turning point involving significant metabolic, cardiovascular, and bone changes that calls for deliberate prevention.

Zdrowie kobietStrong evidence

Insulin Resistance

A state in which the body's cells respond more weakly to insulin, forcing the pancreas to produce ever-larger amounts of it — the most common, and largely reversible, precursor of type 2 diabetes.

ChorobyStrong evidence

Visceral Fat

Fat tissue that accumulates around the internal organs of the abdominal cavity is metabolically far more active and harmful than subcutaneous fat — even though the two can look similar from the outside.

MetabolizmStrong evidence

Comments (2)

KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.